The anthrax vaccine market size is expected to see strong growth in the next few years. It will grow to $13.8 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The forecast period's growth is expected to be fueled by global security challenges, emerging threats, government procurement initiatives aimed at bolstering defense capabilities, and enhanced pandemic preparedness efforts. Anticipated trends in the forecast period encompass technological advancements in vaccine development, increased accessibility of vaccines in developing countries, a heightened focus on next-generation vaccines, expanded government stockpiling initiatives, and collaborative research efforts aimed at combating infectious diseases.
The anthrax vaccine market is expected to experience significant growth due to the rising prevalence of infectious diseases. Infectious diseases, caused by various pathogens, pose a significant threat to public health, leading to a range of symptoms and sometimes fatal outcomes. Factors contributing to the increased prevalence of infectious diseases include demographic shifts, urbanization, environmental changes, and alterations in human behavior. The anthrax vaccine, primarily designed to protect against anthrax, is being explored for its potential to prevent other infectious diseases, driven by ongoing research into its immunogenic properties and adaptability. As highlighted by the Council on Foreign Relations in February 2023, a considerable percentage of newly discovered or emerging infectious diseases have zoonotic origins, underscoring the need for effective vaccines to mitigate their impact.
Major companies in the anthrax vaccine market are prioritizing the development of innovative products and obtaining FDA approvals to ensure safety, efficacy, and accessibility for individuals at risk of anthrax exposure. FDA approval signifies that a vaccine has undergone rigorous testing in clinical trials and has been deemed safe for public use, providing assurance to individuals regarding its safety profile. For example, Emergent BioSolutions Inc., a leading biopharmaceutical company, received FDA approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) in July 2023. This approval was based on comprehensive Phase 2 and Phase 3 clinical trials evaluating the vaccine's safety and immunogenicity compared to existing anthrax vaccines. Additionally, advancements in adjuvant technology are crucial for addressing reactogenicity concerns and enhancing the overall effectiveness of anthrax vaccines.
In October 2022, the Biomedical Advanced Research and Development Authority (BARDA) partnered with ICON plc and Rho Federal Systems Division Inc. to conduct a clinical trial evaluating the anthrax vaccine AV7909. This trial aims to assess the immunogenicity kinetics of AV7909, which combines the FDA-licensed anthrax vaccine BioThrax with an immune system stimulant. ICON plc, an Ireland-based clinical research organization, and Rho Federal Systems Division Inc., a US-based company specializing in research and development services, are collaborating with BARDA to advance anthrax vaccine research and development.
Major companies operating in the anthrax vaccine market are Merck & Co. Inc., GC Biopharma, Emergent BioSolutions Inc., Indian Immunologicals Limited, Valneva SE, PharmAthene Inc, Porton Biopharma Limited, Pfenex Inc., Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company, Inc., Elusys Therapeutics Inc., SIGA Technologies Inc., Inovio Pharmaceuticals, Botswana Vaccine Institute, JOVAC, Prokarium, Soligenix Inc., Vaxart Inc., DynPort Vaccine Company LLC, VECOL S.A.
North America was the largest region in the anthrax vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anthrax vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The anthrax vaccine is a medical product aimed at conferring immunity against anthrax, a severe infectious disease caused by the bacterium Bacillus anthracis. Comprising an inactivated form of the anthrax bacterium or its components, the vaccine stimulates the body's immune response to generate antibodies against anthrax toxins. Typically administered via injections, the vaccine involves initial doses followed by booster shots to sustain immunity over time.
The primary types of anthrax vaccine include the cell-free protective antigen (PA) vaccine and the live attenuated vaccine. The cell-free protective antigen (PA) vaccine is produced in a laboratory environment without live bacteria, involving the synthesis of the anthrax bacteria's protective antigen (PA) protein. These vaccines find applications in both animal and human use and are distributed through various channels such as hospitals, pharmacies, and others.
The anthrax vaccine market research report is one of a series of new reports that provides anthrax vaccine market statistics, including anthrax vaccine industry global market size, regional shares, competitors with a anthrax vaccine market share, detailed anthrax vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the anthrax vaccine industry. This anthrax vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The anthrax vaccine market consists of sales of avirulent, nonencapsulated bacillus anthracis microaerophilic cultures, aluminum, benzethonium chloride, and formaldehyde. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Anthrax Vaccine Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on anthrax vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for anthrax vaccine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anthrax vaccine market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine; Live Attenuated Vaccine2) By Application Type: Animal Use; Human Use
3) By Distribution Channel: Hospitals; Pharmacies; Other Distribution Channels
Key Companies Mentioned: Merck & Co. Inc.; GC Biopharma; Emergent BioSolutions Inc.; Indian Immunologicals Limited; Valneva SE
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Merck & Co. Inc.
- GC Biopharma
- Emergent BioSolutions Inc.
- Indian Immunologicals Limited
- Valneva SE
- PharmAthene Inc
- Porton Biopharma Limited
- Pfenex Inc.
- Choong Ang Vaccine Laboratories Co. Ltd.
- Colorado Serum Company, Inc.
- Elusys Therapeutics Inc.
- SIGA Technologies Inc.
- Inovio Pharmaceuticals
- Botswana Vaccine Institute
- JOVAC
- Prokarium
- Soligenix Inc.
- Vaxart Inc.
- DynPort Vaccine Company LLC
- VECOL S.A
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | July 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 11.27 Billion |
Forecasted Market Value ( USD | $ 13.8 Billion |
Compound Annual Growth Rate | 5.2% |
Regions Covered | Global |